TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23370075
Drug: Gastroretentive gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastroretentive gabapentin (G-GR) 1800 mg (600 mg AM/1200 mg PM) for 14 weeks
Study: 24521776
Drug: Fluvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (80 mg/d)
Study: 1323501
Drug: Ossein-hydroxyapatite compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ossein-hydroxyapatite compound (OHC) 6.46 g daily for 6 months
Study: 1323501
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no bone protective treatment)
Study: 26659550
Drug: Lurasidone 60
Normalized name: lurasidone 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 60 mg/day
Study: 27611311
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) patches
Study: 17884396
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rate brachytherapy as a boost after external beam chemoradiotherapy
Study: 18160753
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg vitamin C
Study: 12115017
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg vitamin C
Study: 11789184
Drug: Puerarin 400
Normalized name: PUERARIA MIRIFICA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin 400 mg per day intravenously dripping
Study: 9092223
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (n = 834)
Study: 6540129
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (i.v. IgG)
Study: 30370686
Drug: Proximal metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal metformin (1000 mg) + distal saline
Study: 30370686
Drug: Distal metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal metformin (1000 mg) + proximal saline
Study: 28524358
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no-treatment assessment-only)
Study: 25015544
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor monotherapy (darunavir/ritonavir or lopinavir/ritonavir)
Study: 25015544
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug therapy (two nucleos(t)ides)
Study: 20397453
Drug: Drug control
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug control group
Study: 14563515
Drug: Standard-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemotherapy with primary prophylaxis using hemopoietic growth factors
Study: 7769318
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg of base/kg during 3 days or 10 mg of base/kg in one dose) plus primaquine (10 mg/kg during 28 days or 2.5 mg/kg during 3 days)
Study: 7769318
Drug: Halofantrine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (24 mg base/kg in 12 h)
Study: 2182613
Drug: Phosphatidylcholine (lecithin)
Normalized name: phosphatidylcholine, soybean
DrugBank: Lecithin (DB15834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylcholine (lecithin) 20 g/day
Study: 311979
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Peptide-PABA
Study: 311979
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g Peptide-PABA
Study: 19070758
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (20 mg/kg)
Study: 8023802
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of supplements that did not contain carotene
Study: 28533151
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) with salvage radiation therapy (SRT)
Study: 28533151
Drug: ADT use
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT use predictors: presurgery PSA >20 ng/ml (AOR = 1.34, P = 0.002; 36.7% vs. 29.6%), positive margins (AOR = 1.29, P = 0.001; 34.9% vs. 27.8%), Gleason scores (Gleason 3+4 AOR = 1.53; 21.3%, 4+3 AOR = 2.40; 32.0%, 8 to 10 AOR = 4.49; 49.2% vs. 2 to 6; P≤0.005 for all; 13.2%), pathologic T stages (T3a AOR = 1.46; 30.9%, T3b AOR = 2.50; 47.6%, T4 AOR = 4.14; 60.9% vs. T2; P<0.001 for all; 19.1%).
Study: 18937325
Drug: DTP vaccine
Normalized name: DTP Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP vaccine (three doses administered)
Study: 10193254
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 1 ppm
Study: 3396485
Drug: Long course
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long course prophylaxis (2g cefotaxime at anaesthesia plus 7 doses of 1g 12‐hourly)
Study: 3396485
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (short and long course)
Study: 29119704
Drug: RP5063 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP5063 (10 mg fasting, 15 mg fed/fasting)
Study: 29119704
Drug: RP5063 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP5063 (10, 20, 50, and 100 mg fed)
Study: 29119704
Drug: RP5063 (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP5063 (single-dose study)
Study: 28374849
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg every 2 weeks
Study: 20642207
Drug: FAHF‐2 (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAHF‐2 (2.2 g, 3 times a day for 7 days)
Study: 20642207
Drug: FAHF‐2 (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAHF‐2 (3.3 g, 3 times a day for 7 days)
Study: 20642207
Drug: FAHF‐2 (6.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAHF‐2 (6.6 g, 3 times a day for 7 days)
Study: 12682474
Drug: Stress doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress doses of hydrocortisone (100 mg before induction of anesthesia, then 10 mg/hr for 24 hrs, 5 mg/hr for 24 hrs, 3 x 20 mg/day, and 3 x 10 mg/day)
Study: 9184782
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (15 mg/day)
Study: 8197889
Drug: Minimal contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal contact self-help treatment control
Study: 3581712
Drug: 3 weeks'
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks' anticoagulation with heparin and warfarin
Study: 3581712
Drug: 6 weeks'
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weeks' anticoagulation with heparin and warfarin
Study: 18604331
Drug: Celecoxib (accumulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (accumulated dose of 400 mg)
Study: 18604331
Drug: Meloxicam (accumulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (accumulated dose of 15 mg)
Study: 16311277
Drug: Magnesium 40
Normalized name: Magnesium 400mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium 40 mg kg(‐1) bolus followed by magnesium 10 mg kg(‐1) h(‐1) infusion
Study: 16311277
Drug: Magnesium 40
Normalized name: Magnesium 400mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium 40 mg kg(‐1) bolus followed by magnesium 20 mg kg(‐1) h(‐1) infusion
Study: 3083718
Drug: 0.02 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg/kg nicardipine
Study: 7762855
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg diltiazem
Study: 3940258
Drug: Lidamidine 12
Normalized name: lidamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidamidine 12 mg
Study: 3940258
Drug: Lidamidine 18
Normalized name: lidamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidamidine 18 mg
Study: 30355119
Drug: Prior intravenous
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior intravenous thrombolysis
Study: 22219343
Drug: I.V. acetazolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. acetazolamide (ACZ) 10 mg kg⁻¹
Study: 18383657
Drug: Sucking ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucking ice during chemotherapy
Study: 18383657
Drug: Analgesics (especially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics (especially morphine)
Study: 12753443
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with bupivacaine 0.22% 4 mg.kg‐1 (1.8 ml.kg‐1) and morphine 150 microg x kg‐1
Study: 8565196
Drug: MethaSite (0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MethaSite (0.1% fluorometholone gel‐forming suspension)
Study: 8565196
Drug: FML S.O.P.
Normalized name: FML S.O.P.
Approvals — FDA: no, EMA: no, PMDA: no
Description: FML S.O.P. (0.1% fluorometholone ointment)
Study: 2016630
Drug: Prophylactic vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic vancomycin 15 mg/kg every 12 hours from day -2 until resolution of neutropenia or until the first episode of fever
Study: 7224109
Drug: Rechallenge with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rechallenge with the same allergen or a dissimilar challenging agent
Study: 7224109
Drug: Rechallenge with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rechallenge with an unrelated allergen or compound 48/80
Study: 17304143
Drug: Mesalazine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine (4 g/day)
Study: 28687413
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg three times per week for 48 weeks
Study: 19507456
Drug: e/Tablet electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: e/Tablet electronic format
Study: 16550416
Drug: Psychiatric day‐hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric day‐hospital treatment
Study: 9820992
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment to lower serum cholesterol
Study: 2572495
Drug: Sulfasalazine prophylaxis
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine prophylaxis (3 g daily for at least 2 years)
Study: 336304
Drug: 1.05 mg
Normalized name: thiamine 1.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.05 mg atropine
Study: 18782903
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg terbutaline
Study: 31754238
Drug: 8-month daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-month daily after-school aerobic exercise program (40 min/day, n=90)
Study: 31718297
Drug: Invasive strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive strategy in addition to optimal medical therapy
Study: 17003303
Drug: Intensive multifactorial
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multifactorial pharmacological treatment
Study: 12770610
Drug: AIT-082 100
Normalized name: AIT-034
DrugBank: AIT-034 (DB06106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIT-082 100 mg/day
Study: 12770610
Drug: AIT-082 500
Normalized name: AIT-034
DrugBank: AIT-034 (DB06106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIT-082 500 mg/day
Study: 12770610
Drug: AIT-082 2000
Normalized name: AIT-034
DrugBank: AIT-034 (DB06106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIT-082 2000 mg/day
Study: 12770610
Drug: AIT-082 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIT-082 (all doses)
Study: 9298381
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous drip infusion for 12-24 hours
Study: 9298381
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative intravenous drip infusion
Study: 3793337
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (CC)
Study: 27449404
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 ml)
Study: 27117440
Drug: Testosterone solution
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone solution 2% (T-sol)
Study: 24642148
Drug: tamsulosin (0.4mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin (0.4mg, three doses: 14 and 2 hours before, and 10 hours after surgery)
Study: 22181338
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (GBE) 120 mg/day for one month (n=10)
Study: 17947726
Drug: Capecitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1,000 mg/m2 twice daily for 2 weeks, followed by a 1-week break) + Erlotinib (150 mg daily)
Study: 15678055
Drug: TP‐10 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP‐10 (10 mg/kg)
Study: 12841536
Drug: Methimazole (MMI)
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (MMI) therapy, 10-30 mg for the first month and 5-10 mg from the second to the twelfth month.
Study: 12841536
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group 2) with normal serum TSH at the end of the first month of MMI therapy.
Study: 10812235
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated VZV vaccine (4000 PFU)
Study: 10812235
Drug: Inactivated VZV
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated VZV vaccine (equal volume to live vaccine)
Study: 9678125
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives started on the first day of menses (day 1 group)
Study: 9678125
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives started on the fifth day after the onset of menses (day 5 group)
Study: 1497039
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (larger dose increments of oxytocin)
Study: 1497039
Drug: Traditional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional group (standard dose increments of oxytocin)
Study: 29497121
Drug: Rupatadine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 40 mg daily
Study: 27236887
Drug: Yiqi Fumai
Normalized name: Aspergillus fumigatus allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Fumai Lyophilized Powder (5.2 g in 500 mL normal saline)
Study: 23479999
Drug: Furasidine potassium
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furasidine potassium (furamag) 50 mg t.i.d. for 7 days
Study: 23479999
Drug: Phosphomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phosphomycin trometamol (monural) 3 g single dose for pulse therapy
Study: 20459883
Drug: Aripiprazole at
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole at 5‐15 mg/d
Study: 16253975
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg twice daily) for 6 months
Study: 15576654
Drug: RAS blockers
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RAS blockers (RASb) and acetylsalicylic acid (ASA)
Study: 7754886
Drug: Bowel cleansing
Normalized name: Dulcolax Bowel Cleansing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel cleansing with laxatives and allowed to eat (Group 1)
Study: 7754886
Drug: Bowel cleansing
Normalized name: Dulcolax Bowel Cleansing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel cleansing with laxatives and liquid supper followed by fasting (Group 2)
Study: 7754886
Drug: Laxatives before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxatives before examination (Groups 1 and 2 combined)
Study: 7754886
Drug: No laxatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: No laxatives (Groups 3 and 4 combined)
Study: 6986827
Drug: Azathioprine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2 mg/kg of body weight per day) with prednisone (60 mg per day)
Study: 6986827
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with prednisone (60 mg per day)
Study: 31075401
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment group (cotrimoxazole 59.5%, quinolones 21.4%)
Study: 31075401
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment group
Study: 31075401
Drug: Carbapenem treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbapenem treatment
Study: 30716802
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus voice therapy (Group B)
Study: 30716802
Drug: Medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alone (Group A)
Study: 26462480
Drug: IV ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ibandronate 1 mg/month
Study: 26462480
Drug: Oral risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral risedronate 2.5 mg/day
Study: 24856782
Drug: Aluminium hydroxide
Normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium hydroxide adjuvanted HNVAC vaccine
Study: 24856782
Drug: Non-adjuvanted HNVAC
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted HNVAC vaccine
Study: 22114792
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (EPA 510 mg + DHA 340 mg)
Study: 22114792
Drug: Placebo (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (850 mg)
Study: 19461257
Drug: Enhanced community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced community treatment
Study: 11680399
Drug: Ropivacaine infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine infiltration 1.5 mg/ml plus adrenaline 1/200,000 in normal saline 100 ml
Study: 11680399
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 100 ml plus adrenaline 1/200,000
Study: 3311191
Drug: Delayed administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed administration of CyA following ATG treatment (group CyA)
Study: 3311191
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment including ATG (group STD)
Study: 3311191
Drug: Delayed administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed administration of CyA
Study: 25696967
Drug: basal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: basal therapy
Study: 21360528
Drug: Videoconference (VC)
Normalized name: phenylephrine hydrochloride / promethazine hydrochloride Oral Solution [Phenergan VC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videoconference (VC) delivery of cognitive-behavioral anger management treatment (AMT)
Study: 21360528
Drug: In-person delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person delivery of cognitive-behavioral anger management treatment (AMT)
Study: 14552179
Drug: D‐panthenol (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐panthenol (5% drops and 5% gel)
Study: 10468503
Drug: L‐N(G) methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐N(G) methyl arginine hydrochloride (L‐NMMA) 6 mg/kg intravenous infusion
Study: 10468503
Drug: L‐N(G) methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐N(G) methyl arginine hydrochloride (L‐NMMA)
Study: 7782110
Drug: amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxycillin 500 mg/clavulanic acid 125 mg t.i.d.
Study: 2212255
Drug: Intestinal decontamination
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intestinal decontamination (tobramycin 80 mg and colistin 100 mg, four times daily via gastric tube)
Study: 27324882
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy plus standard drug treatment
Study: 365289
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug treatment alone
Study: 19789937
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser treatment (810-nm, 2 W)
Study: 9563139
Drug: 1-month depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month depot (3.75 mg leuprorelin acetate)
Study: 9563139
Drug: 3-month depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-month depot (11.25 mg leuprorelin acetate)
Study: 7885968
Drug: Cefepime (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (1-2 g every 8-12 hours)
Study: 3199913
Drug: Combination clinical/telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination clinical/telephone interventions
Study: 27686283
Drug: BioNet's aP
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioNet's aP vaccine
Study: 27686283
Drug: BioNet's TdaP
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioNet's TdaP vaccine
Study: 27686283
Drug: Adacel® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adacel® vaccine
Study: 8147095
Drug: All vaccine
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All vaccine groups
Study: 14681341
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg single oral dose